Who is the sponsor?
Emmes Coporation and National Eye Institute(NEI)
Who are the patients?
Participants with macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) who are 18 years of age or older and are willing to provide consent may be eligible for the SCORE Study. The participating doctor will evaluate you to determine your eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.
How long are the eligible patients enrollment?
3 years
When did participation agreement start at our site?
August 2004
What is the enrollment goal for the sponsor?
972 participants: 486 CRVO participants and 486 BRVO participants.
Is the enrollment still open?
No
What is this study investigating?
This is a multi-center, randomized Phase III trial study designed to assess the efficacy and safety of standard care versus triamcinolone acetonide injection(s) for the treatment of macular edema associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) with the follow objectives: Compare visual acuity outcome among 3 groups of participants: Those who are randomly assigned to receive standard care. Those randomly assigned to receive one of two doses of intravitreal injection(s) of triamcinolone acetonide for treatment of macular edema associated with central retinal vein occlusion (CRVO). Those randomly assigned to receive one of two doses of intravitreal injection(s) of triamcinolone acetonide for treatment of macular edema associated with branch retinal vein occlusion (BRVO).
How is the treatment administered?
Laser photocoagulation or Intravitreal injection